{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:04Z","timestamp":1761896284669,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12933-016-0355-z","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:58:54Z","timestamp":1456275534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events"],"prefix":"10.1186","volume":"15","author":[{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fady T.","family":"Botros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Atisso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip T.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"355_CR1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215\u201322.","journal-title":"Lancet"},{"key":"355_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","volume":"30","author":"JB Buse","year":"2007","unstructured":"Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162\u201372.","journal-title":"Diabetes Care"},{"key":"355_CR3","unstructured":"National diabetes fact sheet (CDC). National estimates and general information on diabetes and prediabetes in the United States. http:\/\/www.familydocs.org\/f\/CDC%20Diabetes%20fact%20sheet-2011.pdf ."},{"key":"355_CR4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","volume":"292","author":"CS Fox","year":"2004","unstructured":"Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D\u2019Agostino RB Sr, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495\u20139.","journal-title":"JAMA"},{"key":"355_CR5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434\u201344.","journal-title":"Diabetes Care"},{"key":"355_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11892-015-0663-9","volume":"15","author":"B Hirshberg","year":"2015","unstructured":"Hirshberg B, Katz A. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. Curr Diab Rep. 2015;15:87. doi: 10.1007\/s11892-015-0663-9 .","journal-title":"Curr Diab Rep"},{"key":"355_CR7","unstructured":"United States Food and Drug Administration Guidance for Industry, Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008 FDA guidance document. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf ."},{"key":"355_CR8","unstructured":"Guideline on Clinical Investigation in Treatment and Prevention of Diabetes Mellitus. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129256.pdf ."},{"key":"355_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/dmrr.538","volume":"21","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91\u2013117.","journal-title":"Diabetes Metab Res Rev"},{"key":"355_CR10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"355_CR11","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288\u201398.","journal-title":"Diabetologia"},{"key":"355_CR12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","volume":"26","author":"W Glaesner","year":"2010","unstructured":"Glaesner W, Mark Vick A, Millican R, Ellis B, Tschang SH, Tian Y, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287\u201396.","journal-title":"Diabetes Metab Res Rev"},{"key":"355_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3810\/pgm.2014.10.2821","volume":"126","author":"L Kuritzky","year":"2014","unstructured":"Kuritzky L, Umpierrez G, Ekoe JM, Mancillas-Adame L, Lando LF. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126:60\u201372.","journal-title":"Postgrad Med"},{"key":"355_CR14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1463-1326.2011.01366.x","volume":"13","author":"GE Umpierrez","year":"2011","unstructured":"Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ, 3rd, Group EGOS. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight\/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418\u201325.","journal-title":"Diabetes Obes Metab"},{"key":"355_CR15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1464-5491.2012.03745.x","volume":"29","author":"G Grunberger","year":"2012","unstructured":"Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12\u00a0weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260\u20137.","journal-title":"Diabet Med"},{"key":"355_CR16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1507\/endocrj.EJ14-0147","volume":"61","author":"Y Terauchi","year":"2014","unstructured":"Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12\u00a0weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61:949\u201359.","journal-title":"Endocr J"},{"key":"355_CR17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731\u20137.","journal-title":"Hypertension"},{"key":"355_CR18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159\u201367.","journal-title":"Diabetes Care"},{"key":"355_CR19","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide vs. insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241\u20139.","journal-title":"Diabetes Care"},{"key":"355_CR20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168\u201376.","journal-title":"Diabetes Care"},{"key":"355_CR21","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","volume":"385","author":"L Blonde","year":"2015","unstructured":"Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057\u201366.","journal-title":"Lancet"},{"key":"355_CR22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/dom.12305","volume":"16","author":"Z Skrivanek","year":"2014","unstructured":"Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16:748\u201356.","journal-title":"Diabetes Obes Metab"},{"key":"355_CR23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849\u201358.","journal-title":"Diabetes Obes Metab."},{"key":"355_CR24","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136\/bmj.b2700 .","journal-title":"BMJ"},{"key":"355_CR25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober KV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"355_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1479164111408937","volume":"8","author":"SP Marso","year":"2011","unstructured":"Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237\u201340.","journal-title":"Diab Vasc Dis Res"},{"key":"355_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-10-22","volume":"10","author":"R Ratner","year":"2011","unstructured":"Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.","journal-title":"Cardiovasc Diabetol"},{"key":"355_CR28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","volume":"3","author":"M Fisher","year":"2015","unstructured":"Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJV. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697\u2013703.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"355_CR29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/dom.12448","volume":"17","author":"SR Seshasai","year":"2015","unstructured":"Seshasai SR, Bennett RL, Petrie JR, Bengus M, Ekman S, Dixon M, et al. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:505\u201310.","journal-title":"Diabetes Obes Metab"},{"key":"355_CR30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-11-6","volume":"11","author":"ME Cobble","year":"2012","unstructured":"Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6.","journal-title":"Cardiovasc Diabetol"},{"key":"355_CR31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1463-1326.2010.01215.x","volume":"12","author":"A Schweizer","year":"2010","unstructured":"Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"355_CR32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","volume":"114","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788\u2013803.","journal-title":"Circ Res"},{"key":"355_CR33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1463-1326.2010.01345.x","volume":"13","author":"P Anagnostis","year":"2011","unstructured":"Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13:302\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"3 Suppl","key":"355_CR34","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/j.amjcard.2011.03.046","volume":"108","author":"MH Davidson","year":"2011","unstructured":"Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108(3 Suppl):33B\u201341B.","journal-title":"Am J Cardiol"},{"key":"355_CR35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12933-015-0188-1","volume":"14","author":"K Torimoto","year":"2015","unstructured":"Torimoto K, Okada Y, Mori H, Otsuka T, Kawaguchi M, Matsuda M, et al. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:25.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"355_CR36","doi-asserted-by":"crossref","first-page":"e0135854","DOI":"10.1371\/journal.pone.0135854","volume":"10","author":"H Nomoto","year":"2015","unstructured":"Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, et al. A comparison of the effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial Sapporo Athero-Incretin Study 2 (SAIS2). PLoS One. 2015;10(8):e0135854. doi: 10.1371\/journal.pone.0135854 .","journal-title":"PLoS One"},{"key":"355_CR37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12933-015-0279-z","volume":"14","author":"R Sim\u00f3","year":"2015","unstructured":"Sim\u00f3 R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzm\u00e0n J, Dotta F, et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol. 2015;14:116.","journal-title":"Cardiovasc Diabetol"},{"key":"355_CR38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-015-0178-3","volume":"14","author":"SK Paul","year":"2015","unstructured":"Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol. 2015;14:10.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"355_CR39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DMSO.S34418","volume":"10","author":"T Gurung","year":"2015","unstructured":"Gurung T, Shyangdan DS, O\u2019Hare JP, Waugh N. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes. 2015;10(8):363\u201386. doi: 10.2147\/DMSO.S34418 .","journal-title":"Diabetes Metab Syndr Obes"},{"key":"355_CR40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10354-010-0748-7","volume":"160","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr. 2010;160:8\u201319.","journal-title":"Wien Med Wochenschr"},{"key":"355_CR41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765\u201372.","journal-title":"Lancet"},{"key":"355_CR42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med."},{"key":"355_CR43","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","volume":"372","author":"RA Hayward","year":"2015","unstructured":"Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197\u2013206.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-016-0355-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T02:40:22Z","timestamp":1498272022000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cardiab.com\/content\/15\/1\/38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s12933-016-0355-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2016,2,24]]},"article-number":"38"}}